Intermittent Explosive Disorder
14
5
5
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
14.3%
2 terminated out of 14 trials
75.0%
-11.5% vs benchmark
21%
3 trials in Phase 3/4
67%
4 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (14)
Inflammatory Challenge in Human Aggression.
Effect of Nitrous Oxide on Aggression.
Pimavanserin and Aggression and Social Cognition.
Neural Correlates During Alcohol Intoxication
Psychotherapy for Intermittent Explosive Disorder
Maladaptive Anger Treatment
Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder
A Cognitive Bias Modification RCT for Aggression
Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder
Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.
Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order
A Pilot Study Comparing the Efficacy of Group Versus Individual Anger Management in Subjects With IED